Estrogen receptor α (ERα) is a marker predictive for response of breast cancers to endocrine therapy. About 30% of breast cancers, however, are hormone- independent because of lack of ERα expression. New strategies are needed for re-expression of ERα and sensitization of ER-negative breast cancer cells to selective ER modulators. The present report shows that arsenic trioxide induces reactivated ERα, providing a target for therapy with ER antagonists. Exposure of ER-negative breast cancer cells to arsenic trioxide leads to re-expression of ERα mRNA and functional ERα protein in in vitro and in vivo. Luciferase reporter gene assays and 3-(4,5-dimethylthiazol-2-yl)- 5-(3-carboxymethoxyphenyl)- 2-(4-sulfophenyl)- 2H-tetrazolium (MTS) assays show that, upon exposure to arsenic trioxide, formerly unresponsive, ER-negative MDA-MB-231 breast cancer cells become responsive to ER antagonists, 4-hydroxytamoxifen and ICI 182,780. Furthermore, methylation- specific PCR and bisulfite-sequencing PCR assays show that arsenic trioxide induces partial demethylation of the ERα promoter. A methyl donor, S-adenosylmethionine (SAM), reduces the degree of arsenic trioxide-induced re-expression of ERα and demethylation. Moreover, Western blot and ChIP assays show that arsenic trioxide represses expression of DNMT1 and DNMT3a along with partial dissociation of DNMT1 from the ERα promoter. Thus, arsenic trioxide exhibits a previously undefined function which induces re-expression ERα in ER-negative breast cancer cells through demethylation of the ERα promoter. These findings could provide important information regarding the application of therapeutic agents targeting epigenetic changes in breast cancers and potential implication of arsenic trioxide as a new drug for the treatment of ER–negative human breast cancer.
References
[1]
Giacinti L, Claudio PP, Lopez M, Giordano A (2006) Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11: 1–8.
[2]
McGuire WL (1978) Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428–433.
[3]
Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, et al. (2001) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61: 7025–7029.
[4]
Lapidus RG, Nass SJ, Davidson NE (1998) The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 3: 85–94.
[5]
Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21: 5462–5482.
[6]
Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117: 3155–3163.
[7]
Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, et al. (1998) Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 58: 2515–2519.
[8]
Bird AP (1986) CpG-rich islands and the function of DNA methylation. Nature 321: 209–213.
[9]
Davison K, Mann KK, Miller WH Jr (2002) Arsenic trioxide: mechanisms of action. Semin Hematol 39: 3–7.
[10]
Mass MJ, Wang L (1997) Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 386: 263–277.
[11]
Takeyoshi M, Yamasaki K, Sawaki M, Nakai M, Noda S, et al. (2002) The efficacy of endocrine disruptor screening tests in detecting anti-estrogenic effects downstream of receptor-ligand interactions. Toxicol Lett 126: 91–98.
[12]
Liu H, Du J, Hu C, Qi H, Wang X, et al. (2010) Delayed activation of extracellular-signal-regulated kinase 1/2 is involved in genistein- and equol-induced cell proliferation and estrogen-receptor-alpha-mediated transcription in MCF-7 breast cancer cells. J Nutr Biochem 21: 390–396.
[13]
Price JE, Polyzos A, Zhang RD, Daniels LM (1990) Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50: 717–721.
[14]
Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29: 2905–2919.
[15]
Sharma D, Saxena NK, Davidson NE, Vertino PM (2006) Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res 66: 6370–6378.
[16]
Platet N, Cathiard AM, Gleizes M, Garcia M (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51: 55–67.
[17]
Johnston SR, Dowsett M, Smith IE (1992) Towards a molecular basis for tamoxifen resistance in breast cancer. Ann Oncol 3: 503–511.
[18]
Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, et al. (1995) Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 87: 446–451.
[19]
Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, et al. (1994) Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 54: 2552–2555.
[20]
Billam M, Witt AE, Davidson NE (2009) The silent estrogen receptor: Can we make it speak? Cancer Biol Ther 8:
[21]
Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, et al. (2000) Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60: 6890–6894.
[22]
Zhang W, Wang L, Fan Q, Wu X, Wang F, et al. (2011) Arsenic trioxide re-sensitizes ERalpha-negative breast cancer cells to endocrine therapy by restoring ERalpha expression in vitro and in vivo. Oncol Rep 26: 621–628.
[23]
Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-435 cells are derived from M14 melanoma cells – a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104: 13–19.
[24]
Stoica A, Pentecost E, Martin MB (2000) Effects of arsenite on estrogen receptor-alpha expression and activity in MCF-7 breast cancer cells. Endocrinology 141: 3595–3602.
[25]
Chow SK, Chan JY, Fung KP (2004) Suppression of cell proliferation and regulation of estrogen receptor alpha signaling pathway by arsenic trioxide on human breast cancer MCF-7 cells. J Endocrinol 182: 325–337.
[26]
Fishman J, Osborne MP, Telang NT (1995) The role of estrogen in mammary carcinogenesis. Ann N Y Acad Sci 768: 91–100.
[27]
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, et al. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89: 3345–3353.
[28]
Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, et al. (2000) Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14: 262–270.
[29]
Zhang P, Wang S, Hu L, Qiu F, Yang H, et al. (2000) [Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide – an analysis of 242 cases]. Zhonghua Xue Ye Xue Za Zhi 21: 67–70.
[30]
Kito M, Matsumoto K, Wada N, Sera K, Futatsugawa S, et al. (2003) Antitumor effect of arsenic trioxide in murine xenograft model. Cancer Sci 94: 1010–1014.
[31]
Li JQ, Li Y, Shi YJ, Wu SL (2004) [Re-expression of p16 gene in myeloma cell line U266 by arsenic trioxide]. Ai Zheng 23: 626–630.
[32]
Wang MM, Dou HJ, Zou LF, Zhu Q, Ren ZH, et al. (2008) [Correlation of cell cycle alteration to SOCS-1 gene demethylation induced by arsenic trioxide in myeloma cell lines]. Ai Zheng 27: 1150–1154.
[33]
Yang L, Luo JM, Wen SP, Liu XJ, Du XY, et al. (2009) Effect of As2O3 on demethylation of SHP-1 gene in human lymphoma cell line T2. Chin J Cancer 28: 209–213.
[34]
Vahter M (2002) Mechanisms of arsenic biotransformation. Toxicology 181–182: 211–217.
[35]
Gonzalez-Fraile MI, Garcia-Sanz R, Mateos MV, Balanzategui A, Gonzalez M, et al. (2002) Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis. Br J Haematol 117: 890–892.
[36]
Compere SJ, Palmiter RD (1981) DNA methylation controls the inducibility of the mouse metallothionein-I gene lymphoid cells. Cell 25: 233–240.
[37]
Waalkes MP, Miller MS, Wilson MJ, Bare RM, McDowell AE (1988) Increased metallothionein gene expression in 5-aza-2′-deoxycytidine-induced resistance to cadmium cytotoxicity. Chem Biol Interact 66: 189–204.
[38]
Hu Y, Su L, Snow ET (1998) Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition of DNA repair enzymes. Mutat Res 408: 203–218.
[39]
Tong H, Lin M (2002) [Arsenic trioxide induced p15INK4B gene expression in myelodysplastic syndrome cell line MUTZ-1]. Zhonghua Xue Ye Xue Za Zhi 23: 638–641.
[40]
Crooks PA, Tribe MJ, Pinney RJ (1984) Inhibition of bacterial DNA cytosine-5-methyltransferase by S-adenosyl-L-homocysteine and some related compounds. J Pharm Pharmacol 36: 85–89.
[41]
Bechthold A, Floss HG (1994) Overexpression of the thiostrepton-resistance gene from Streptomyces azureus in Escherichia coli and characterization of recognition sites of the 23S rRNA A1067 2′-methyltransferase in the guanosine triphosphatase center of 23S ribosomal RNA. Eur J Biochem 224: 431–437.
[42]
Li Q, Bartlett DL, Gorry MC, O'Malley ME, Guo ZS (2009) Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. Mol Pharmacol 76: 1072–1081.
[43]
Cui X, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K, et al. (2006) Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Hum Pathol 37: 298–311.
